Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chubb
Farmers Insurance
Healthtrust
Dow
Merck
Chinese Patent Office
UBS
Cantor Fitzgerald
Queensland Health

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,618,076

« Back to Dashboard

Summary for Patent: 8,618,076
Title:Nucleoside phosphoramidates
Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Inventor(s): Ross; Bruce S. (Plainsboro, NJ), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (Plainsboro, NJ), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (Ellicott City, MD), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Glen Rock, NJ)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:13/076,552
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 8,618,076

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir TABLET;ORAL 208341-001 Jun 28, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Subscribe
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-001 Oct 10, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Subscribe
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-001 Dec 6, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Subscribe
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,618,076

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,563,530 Purine nucleoside phosphoramidate ➤ Subscribe
9,206,217 Nucleoside phosphoramidates ➤ Subscribe
8,735,569 Nucleoside phosphoramidates ➤ Subscribe
9,637,512 Nucleoside phosphoramidates ➤ Subscribe
8,859,756 Stereoselective synthesis of phosphorus containing actives ➤ Subscribe
8,629,263 Nucleoside phosphoramidates ➤ Subscribe
8,633,309 Nucleoside phosphoramidates ➤ Subscribe
8,642,756 Nucleoside phosphoramidates ➤ Subscribe
9,284,342 Nucleoside phosphoramidates ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,618,076

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 3515 ➤ Subscribe
Argentina 080819 ➤ Subscribe
Argentina 080870 ➤ Subscribe
Argentina 081813 ➤ Subscribe
Argentina 082937 ➤ Subscribe
Australia 2010249481 ➤ Subscribe
Australia 2011235044 ➤ Subscribe
Australia 2011235112 ➤ Subscribe
Brazil 112012024884 ➤ Subscribe
Brazil 112012024923 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Moodys
Fish and Richardson
US Department of Justice
Medtronic
Chinese Patent Office
Citi
Deloitte
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot